Vifor Pharma and Fresenius Kabi Collaborate to Establish Joint Venture in China

 Vifor Pharma and Fresenius Kabi Collaborate to Establish Joint Venture in China

Vifor Pharma and Fresenius Kabi Collaborate to Establish Joint Venture in China

Shots:

  • The companies partnered to form JV focusing on the marketing, market access, and medical affairs activities for the IV iron portfolio. Vifor Pharma will own 55% while the Fresenius Kabi retains 45% of the new JV and is responsible for the commercialization of IV iron portfolio in China
  • The new JV will combine Vifor’s iron deficiency portfolio with Fresenius Kabi’s commercial presence in China and will focus on patient blood management (PBM) benefiting patients and HCPs
  • Vifor Pharma’s IV iron therapies are an innovative therapeutic option, allowing the effective management of patient’s blood and are used to treat IDA and other therapeutic areas

Click here ­to­ read full press release/ article | Ref: Vifor Pharma | Image: Global pharma update

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post